Stage IV Cutaneous Melanoma AJCC v6 and v7 Recruiting Phase 2 Trials for Relatlimab (DB14851)

IndicationStatusPhase
DBCOND0091050 (Stage IV Cutaneous Melanoma AJCC v6 and v7)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02519322Neoadjuvant and Adjuvant Checkpoint BlockadeTreatment